Emerging SARS-CoV-2 Omicron Sub-Variants JN.1 and NB.1.8.1: Genomic Evolution, Implications, and Public Health Perspectives for a variant under monitoring (VuM)

Since the onset of the COVID-19 pandemic, SARS-CoV-2 has undergone continual evolution, culminating in the emergence of multiple variants of concern (VOCs) and interest (VOIs). The Omicron (B.1.1.529) and it’s sub-lineage have dominated recent global transmission due to their enhanced infectivity and immune evasion. This review focuses on two emerging Omicron sub-variants, JN.1 and NB.1.8.1, analysing their genomic mutations, functional consequences, and public health implications. JN.1, derived from the BA.2.86 lineage (Pirola), features the unique L455S mutation in the receptor-binding domain (RBD), enhancing ACE2 binding affinity and contributing to significant immune escape. NB.1.8.1, a recombinant sub-lineage of XBB.1.9.2, accumulates multiple RBD mutations—S486P, V445P, and N460K—demonstrating convergent evolution and notable growth advantage in regions like India and the UK. Despite their increased transmissibility and capacity for immune evasion, preliminary clinical data suggest that both sub-variants lead to predominantly mild infections, likely due to population-level hybrid immunity. However, the evolving mutation profiles raise concerns regarding reduced efficacy of monoclonal antibody therapies and the durability of vaccine protection. Comparative analyses highlight these sub-variants’ refined evolution from earlier lineages such as Alpha, Delta, and BA.1, with functional mutations enhancing both viral fitness and immune escape without compromising replication. Thus implies importance of robust genomic surveillance, continuous vaccine efficacy evaluation, and development of broad-spectrum therapeutics. It calls for a One Health approach that integrates virological, immunological, and public health data to anticipate and respond to emerging variants. JN.1 and NB.1.8.1 exemplify the virus’s adaptive strategies under immune pressure and necessitate updated risk assessments, tailored mitigation strategies, and proactive communication to navigate the next phase of the pandemic.